In patients with early-stage NSCLC, tumor-infiltrating NK cells demonstrate diminished expression of activating receptors (NKp30, NKp80, CD16, and CD226) alongside reduced degranulation capacity and cytokine production39. This evidence concerns the gene CD226 and neoplasm.